CAR-T Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "CAR-T Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from CAR-T Pipeline Report

* DelveInsight's CAR-T Therapy pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for CAR-T Therapy treatment.
* The leading CAR-T Companies such as Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Atara Biotherapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals, and others.
* Promising CAR-T Therapies such as IM23, C-CAR066, AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells, Fludarabine, Cyclophosphamide, and others.
* April 2024:- Stiftung Swiss Tumor Institute- This study is designed as a feasibility study implementing electronic Patient Reported Outcomes (ePRO) in CAR T treatment for hematological malignancies, in order to describe AE reporting. ePRO assessments will be explored for their feasibility to engage in monitoring and management of CAR T-related toxicities as well as using these digital ePRO tools may improve both, its safety and accessibility.

Explore our comprehensive CAR-T Pipeline Report to stay informed about the latest advancements. Download copy now @ CAR-T Pipeline Outlook [https://www.delveinsight.com/sample-request/car-t-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

CAR-T Overview

CAR-T (Chimeric Antigen Receptor T-cell) therapy represents a groundbreaking approach in the field of cancer treatment. This innovative immunotherapy harnesses a patient's own immune system to combat cancer by genetically modifying T-cells to recognize and attack cancer cells more effectively. The process involves extracting T-cells from a patient's blood, modifying them in a laboratory to express chimeric antigen receptors (CARs) that target specific proteins on cancer cells, and then infusing these engineered cells back into the patient.

CAR-T therapy has demonstrated remarkable success in treating certain types of leukemia and lymphoma, achieving durable remissions in patients who have exhausted other treatment options. While still in its early stages, CAR-T therapy holds immense promise for transforming cancer care, offering hope for patients facing otherwise limited prospects. Continued research and development in this field aim to expand its applicability across different types of cancer and further enhance its efficacy and safety profile.

CAR-T Emerging Drugs Profile

* Descartes-08: Cartesian Therapeutics

Descartes-08 is an autologous anti-B cell maturation antigen (BCMA) mRNA CAR-T. Compared to conventional DNA-based CAR T-cell therapies, mRNA CAR-T is designed not to require preconditioning chemotherapy, has been observed to have predictable and controllable pharmacokinetics, and is designed to avoid the risk of genomic integration. Descartes-08 has been granted Orphan Drug Designation by the US FDA for the treatment of MG, a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Currently, the drug is in Phase II stage of clinical trial for the treatment of autoimmune disorders.

* KYV-101: Kyverna Therapeutics

KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase 1 trial in oncology. Results were published by the NIH in Nature Medicine3. KYV-101 is currently being evaluated in sponsored, open-label, Phase 1/2 trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a complete response to current therapies and are at risk of developing kidney failure. Additionally, FDA's IND clearance has been obtained for Phase 2 trials of KYV-101 for multiple sclerosis and myasthenia gravis, and a Phase I/II trial for systemic sclerosis.

* TX200: Sangamo Therapeutics

TX200 is composed of the patient's own (autologous) regulatory T cells (Tregs) engineered to express a chimeric antigen receptor (CAR) designed to recognize the HLA-A2 protein present on a transplanted kidney and bind to it. TX200 is in development for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. It is in Phase I/II stage of its clinical trial.

* ALLO-605: Allogene Therapeutics

ALLO-605, a next-generation AlloCAR T Trademark known as a TurboCAR Trademark , is an investigational product that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma and other BCMA-positive malignancies. This study uses ALLO-647, Allogene's proprietary monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen. ALLO-605 incorporates Allogene's proprietary TurboCAR technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells. In June 2021, ALLO-605 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed/refractory multiple myeloma. The Phase 1 study evaluating ALLO-605 is underway. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Multiple Myeloma.

* ATA3219: Atara Biotherapeutics

ATA3219 combines the natural biology of unedited T cells with the benefits of an allogeneic therapy. It consists of allogeneic Epstein-Barr virus (EBV)-sensitized T cells that express a CD19 CAR construct for the treatment of CD19+ relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin's lymphoma and B-cell mediated autoimmune diseases including systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]). ATA3219 has been optimized to offer a potential best-in-class profile, featuring off-the-shelf availability. Currently, the drug is in Phase I stage of its clinical trial.

* CB-010 : Caribou Biosciences

CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for the treatment of patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). CB-010 is the first allogeneic CAR-T cell therapy, to our knowledge, in a clinical trial with a PD-1 knockout, a genome-editing strategy designed to improve antitumor activity by limiting premature CAR-T cell exhaustion. CB-010 is being evaluated in the ongoing, open-label, multicenter ANTLER Phase I clinical trial in adults with r/r B-NHL.

Dive into our CAR-T Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ CAR-T Treatment Therapies [https://www.delveinsight.com/sample-request/car-t-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

CAR-T Therapeutics Assessment

There are approx. 180+ key companies which are developing the therapies for CAR-T. The companies which have their CAR-T drug candidates in the most advanced stage, i.e. Phase II include, Cartesian Therapeutics.

DelveInsight's report covers around 200+ products under different phases of clinical development like

* Late-stage products (Phase II and Phase II/III)
* Mid-stage products (Phase II and Phase II/III)
* Early-stage products (Phase I/II and Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Download the CAR-T Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ CAR-T Clinical Trials Assessment [https://www.delveinsight.com/sample-request/car-t-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

CAR-T Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Dive into our detailed CAR-T Pipeline Report to discover ground breaking advancements shaping the future of cancer treatment @ CAR-T Products, Companies, and Unmet Needs [https://www.delveinsight.com/sample-request/car-t-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the CAR-T Pipeline Report

* Coverage- Global
* CAR-T Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* CAR-T Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* CAR-T Companies- Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Atara Biotherapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals, and others.
* CAR-T Therapies- IM23, C-CAR066, AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells, Fludarabine, Cyclophosphamide, and others.

Gain valuable insights into emerging therapies and innovations with our CAR-T Pipeline Report @ CAR-T Market Drivers and Barriers, Future Perspectives and Analyst Views [https://www.delveinsight.com/sample-request/car-t-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* CAR-T: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* CAR-T- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Descartes-08: Cartesian Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ATA3219: Atara Biotherapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* CAR-T Key Companies
* CAR-T Key Products
* CAR-T- Unmet Needs
* CAR-T- Market Drivers and Barriers
* CAR-T- Future Perspectives and Conclusion
* CAR-T Analyst Views
* CAR-T Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cart-pipeline-outlook-report-2024-updated]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.